Market Closed -
Other stock markets
|
After market 01:24:18 pm | |||
28.54 EUR | +0.99% | 28.56 | +0.07% |
May. 13 | COMPUGROUP MEDICAL : Reduced to Neutral by Deutsche Bank | ZD |
May. 09 | Berenberg rates Compugroup at 'Buy' - Target 46 euros | DP |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is in debt and has limited leeway for investment
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.70% | 1.6B | C+ | ||
+18.28% | 342B | B- | ||
+29.05% | 226B | B+ | ||
+9.42% | 159B | B | ||
+13.15% | 57.54B | D+ | ||
+19.11% | 35.74B | C+ | ||
+5.88% | 31.6B | B+ | ||
+163.92% | 30.64B | D+ | ||
+30.79% | 21.62B | B- | ||
+43.48% | 14.97B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COP Stock
- Ratings CompuGroup Medical SE & Co. KGaA